Abstract:

Objective To evaluate Cervista high-risk human papillomavirus （HR-HPV）DNA testing combined with thin cytology test （TCT）in cervical cancer screening. Methods A total of 745 female patients were diagnosed as precancerous lesions or cervical cancer with pathological diagnosis as gold standard. The performance of TCT,Cervista HR-HPV DNA testing and Cervista HR-HPV DNA testing combined with TCT were evaluated. The role of Cervista HR-HPV DNA testing combined with TCT in cervical cancer screening was evaluated. Results The specificity of TCT was the best（50.40%）. The sensitivity and negative predictive value of Cervista HR-HPV DNA testing combined with TCT were 92.51% and 82.31%,which were higher than those of single determinations. Conclusions The determination rate of Cervista HR-HPV DNA testing is higher than that of TCT,the combined determination can improve the sensitivity and negative predictive valve effectively,and can decrease the rate of missed diagnosis and false positive rate.

Key words: High-risk human papillomavirus, DNA, Thin cytology test, Cervical cancer